CEBPA and acute myeloid leukemia: To test this, we analyzed the miR-182 expression distribution in primary normal karyotype AML patient samples with either CEBPA wild-type, CEBPA N-terminal mutation or CEBPA C-terminal mutation (including biallelic mutations) (Supplementary Table 3).